To tackle the high-risk, high-reward obesity market, the company is developing both an injectable and an oral version of the same triple-agonist molecule. The injectable version will enter the clinic first, allowing them to quickly obtain human proof-of-concept and validate the molecule's efficacy before investing heavily in the more complex oral formulation.
Related Insights
The company positions its peptide platform as the ideal middle ground in drug development. They aim to create medicines that are functionally like highly selective, less toxic large biologics (e.g., antibodies) but are structurally designed for the convenience of an oral pill, combining the best attributes of both major drug classes.
The obesity drug market is moving past the "weight loss Olympics." While high efficacy is the entry ticket, new differentiators are emerging. Companies like Wave Life Sciences are focusing on muscle-sparing properties, while Structure is advancing oral GLP-1s. This indicates a maturing market where patient convenience, quality of weight loss, and long-term maintenance are becoming key value drivers.
Protagonist believes its oral IL-23 blocker will not just compete with existing injectables but will capture a new market. They target the over 50% of eligible patients who currently take no therapy due to a dislike of injections or the safety profiles of other oral options, thereby expanding the total addressable market.
Pfizer's licensing deal with Yao Pharma for a Phase 1 oral GLP-1 agonist underscores the immense value placed on convenient obesity treatments. The potential $1.935 billion in milestones for such an early-stage asset highlights big pharma's strategy to pay a premium to enter the next wave of weight-management therapies beyond injectables.
Neurocrine mitigates the high risk of its late-stage psychiatry programs, which have uncertain outcomes until Phase 3, by investing in an obesity asset. This program offers the ability to see clear efficacy signals in early Phase 1B trials, providing faster data for decision-making and balancing portfolio risk and cost.
Acknowledging its late entry into the crowded obesity market, Protagonist consulted key opinion leaders to define the ideal drug profile: an oral "triple G" agonist. By using its peptide platform to build exactly what experts requested, the company aims to leapfrog competitors with a best-in-class product rather than an incremental improvement.
Beyond the initial wave of GLP-1s from Novo and Lilly, the next major competitive front in the obesity market will be monthly injectables. Amgen and Pfizer (via its Metsara acquisition) are poised to lead this race, shifting the focus to dosing convenience and long-term adherence.
Aardvark is specifically developing its oral drug for patients who have lost weight on injectable GLP-1s but want to discontinue them while preventing weight regain. This strategy taps into a massive, underserved future market of patients seeking a more convenient, long-term maintenance solution.
Beyond converting patients from existing injectable therapies, the company's core growth strategy for its oral IL-23 drug is to capture the 50%+ of eligible patients who currently refuse treatment altogether because they dislike injections. This transforms the strategy from market share capture to market creation.
Rather than competing head-to-head, Aardvark's preclinical data shows combining its oral drug with a microdose of a GLP-1 injectable achieves 30% weight loss, far exceeding the GLP-1 alone. This positions their drug as a complementary therapy that enhances the existing standard of care.